Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)
NCT04453280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 695
Last updated 2020-07-01
Summary
The aim of the SARS-CoV-2-CZ-Immunity study is to determine the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Quantitative analysis of anti-SARS-CoV-2-antibodies
Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
- DIAGNOSTIC_TEST
-
SARS-CoV-2 diagnostic rapid test
The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
Sponsors & Collaborators
-
Ministry of Health, Czech Republic
collaborator OTHER_GOV -
Masaryk University
collaborator OTHER -
Institute for Clinical and Experimental Medicine
collaborator OTHER_GOV -
Brno University Hospital
collaborator OTHER -
St. Anne's University Hospital Brno, Czech Republic
collaborator OTHER -
Masaryk Memorial Cancer Institute
collaborator OTHER -
Regional Public Health Office of the South Moravian Region based in Brno, Czech Republic
collaborator UNKNOWN -
Public Health Office of the Capital City of Prague, Czech Republic
collaborator UNKNOWN -
Regional Public Health Office of the Central Bohemian Region based in Prague, Czech Republic
collaborator UNKNOWN -
Institute of Health Information and Statistics of the Czech Republic
lead OTHER_GOV
Principal Investigators
-
Roman Prymula, Prof. · Ministry of Health, Czech Republic
-
Jarmila Rážová, M.D., Ph.D. · Ministry of Health, Czech Republic
-
Ladislav Dušek, Prof. · Institute of Health Information and Statistics of the Czech Republic
-
Dalibor Valík, Prof. · Masaryk Memorial Cancer Institute
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-18
- Primary Completion
- 2020-06-03
- Completion
- 2020-06-03
Countries
- Czechia
Study Locations
More Related Trials
-
Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method
NCT04429620 ·Status: UNKNOWN
-
COVID-19 Immune Repertoire Sequencing
NCT04368143 ·Status: COMPLETED
-
SARS-CoV-2 IgG and IgM Serologic Assays
NCT04562246 ·Status: COMPLETED
-
Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients
NCT04410471 ·Status: UNKNOWN
-
COVID-19 Antibody and Reinfection Study
NCT05365750 ·Status: COMPLETED
-
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
NCT04469634 ·Status: COMPLETED ·Phase: NA
-
A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.
NCT06862531 ·Status: COMPLETED ·Phase: NA
-
COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)
NCT04416308 ·Status: COMPLETED ·Phase: NA
-
Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
NCT05484700 ·Status: UNKNOWN
-
Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19
NCT04367714 ·Status: UNKNOWN
-
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
NCT04543006 ·Status: UNKNOWN ·Phase: NA
-
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
NCT05858502 ·Status: RECRUITING ·Phase: NA
-
Neutralizing Antibody Level After COVID-19 Vaccination
NCT05083026 ·Status: RECRUITING
-
Seroconversion in COVID-19 Recovered Population
NCT04558385 ·Status: COMPLETED
-
Evaluation Study of RDTs Detecting Antibodies Against HCV
NCT04033887 ·Status: COMPLETED
-
Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive
NCT04605952 ·Status: COMPLETED
-
COVID-19 IgG Antibodies in the Serum of Recovered Patients
NCT04470414 ·Status: UNKNOWN
-
COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses
NCT04483908 ·Status: COMPLETED
-
Study of Clinical Features of Patients With Autoimmune Liver Disease Complicated With Covid-19 and the Immune Mechanism Affecting Prognosis
NCT06099626 ·Status: UNKNOWN
-
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
NCT04383587 ·Status: COMPLETED ·Phase: NA
-
Evaluating the Response of the Immune System of People with Long COVID (post SARS-CoV-2)
NCT05131594 ·Status: ENROLLING_BY_INVITATION
-
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
NCT05242159 ·Status: UNKNOWN
-
Characterization of the Immunometabolic Signature in Long COVID-19.
NCT05758480 ·Status: COMPLETED ·Phase: NA
-
UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease
NCT05812612 ·Status: UNKNOWN
-
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
NCT04880174 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA